



23448

PATENT TRADEMARK OFFICE

PATENT APPLICATION

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****In re United States Patent Application of:****Applicant:** CHILKOTI, Ashutosh**Serial No.:** 09/812,382**Date Filed:** March 20, 2001**Priority Date Claimed:** March 20, 2000  
(U.S. Provisional Application 60/190,659)**Title:** FUSION PEPTIDES ISOLATABLE BY  
PHASE TRANSITION**Atty. Docket No.:** 4176-101**Examiner:** Unknown**Group Art Unit:** 1645**FIRST CLASS MAIL CERTIFICATE**

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to the Commissioner for Patents, Washington, DC 20231, and First Class Mailed under the provisions of 37 CFR 1.8.

  
Lynda Montoya


June 1, 2001  
Date of Mailing

**STATEMENT OF IDENTITY UNDER 27 C.F.R. §1.821 (f)**


Commissioner for Patents  
Box PATENT APPLICATION  
Washington, DC 20231

Sir:

I hereby state that I have prepared the paper copy of the document titled "Patent-In 3.0\_sequence listing.ST25" (which are submitted as part of the above-identified application) and recorded such document on computer readable form, and that information recorded in computer readable form is identical to that on the paper copy of sequence listing submitted.



Yongzhi Yang,  
Reg. No. (see attached)



Steven J. Hultquist  
Reg. No. 28,021  
Attorneys for Applicants

**INTELLECTUAL PROPERTY/  
TECHNOLOGY LAW**  
P.O. Box 14329  
Research Triangle Park, NC 27709  
Telephone: (919) 419-9350  
Fax: (919) 419-9354  
**Attorney Ref: 4176-101**



SEQUENCE LISTING

<110> Chilkoti, Ashutosh

<120> Fusion Peptides Isolatable by Phase Transition

<130> 4176-101

<140> US 09/812,382

<141> 2001-03-20

<150> US 60/190,659

<151> 2000-03-20

<160> 7

<170> PatentIn version 3.0

<210> 1

<211> 5

<212> PRT

<213> Artificial

<220>

<223> pentapeptide monomer

<220>

<221> UNSURE

<222> (4)..(4)

<223> X can be any amino acid, natural or non-natural.

<400> 1

Val Pro Gly Xaa Gly

1 5

<210> 2

<211> 5

<212> PRT

<213> Artificial

<220>

<223> Pentapeptide monomer

<220>

<221> UNSURE

<222> (4)..(4)

<223> X can be any amino acid, natural or non-natural.

<400> 2

Ile Pro Gly Xaa Gly  
1 5

<210> 3

<211> 50

<212> PRT

<213> ELP[V5A2G3-10]

<400> 3

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val  
1 5 10 15

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Ala Gly Val Pro  
20 25 30

Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Gly Gly Val Pro Gly  
35 40 45

Gly Gly  
50

<210> 4

<211> 25

<212> PRT

<213> ELP[V-5]

<400> 4

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val  
1 5 10 15

Pro Gly Val Gly Val Pro Gly Val Gly  
20 25

<210> 5

<211> 75

<212> DNA

<213> ELP[V-5]

<400> 5

gtgggtgttc cgggcgtagg tgtcccaggt gtgggcgtac cgggcgttgg tgttcctggt  
60

gtcggcgtgc cgggc  
75

<210> 6  
<211> 450  
<212> PRT  
<213> ELP[V5A2G3-90]

<400> 6

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val  
1 5 10 15  
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Ala Gly Val Pro  
20 25 30  
Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Gly Gly Val Pro Gly  
35 40 45  
Gly Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val  
50 55 60  
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Ala Gly  
65 70 75 80  
Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Gly Gly Val  
85 90 95  
Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro  
100 105 110  
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly  
115 120 125  
Ala Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Gly  
130 135 140  
Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly Val Gly  
145 150 155 160  
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val  
165 170 175  
Pro Gly Ala Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro  
180 185 190

Gly Gly Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly  
 195 200 205  
 Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val  
 210 215 220  
 Gly Val Pro Gly Ala Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly  
 225 230 235 240  
 Val Pro Gly Gly Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val  
 245 250 255  
 Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro  
 260 265 270  
 Gly Val Gly Val Pro Gly Ala Gly Val Pro Gly Ala Gly Val Pro Gly  
 275 280 285  
 Gly Gly Val Pro Gly Gly Gly Val Pro Gly Gly Gly Val Pro Gly Val  
 290 295 300  
 Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly  
 305 310 315 320  
 Val Pro Gly Val Gly Val Pro Gly Ala Gly Val Pro Gly Ala Gly Val  
 325 330 335  
 Pro Gly Gly Gly Val Pro Gly Gly Gly Val Pro Gly Gly Gly Val Pro  
 340 345 350  
 Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly  
 355 360 365  
 Val Gly Val Pro Gly Val Gly Val Pro Gly Ala Gly Val Pro Gly Ala  
 370 375 380  
 Gly Val Pro Gly Gly Gly Val Pro Gly Gly Gly Val Pro Gly Gly Gly  
 385 390 395 400  
 Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val  
 405 410 415  
 Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Ala Gly Val Pro  
 420 425 430  
 Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Gly Gly Val Pro Gly  
 435 440 445

Gly Gly  
450

<210> 7  
<211> 100  
<212> PRT  
<213> ELP[V-20]

<400> 7

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val  
1 5 10 15

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro  
20 25 30

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly  
35 40 45

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val  
50 55 60

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly  
65 70 75 80

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val  
85 90 95

Pro Gly Val Gly  
100